Further Evidence in Favor of Non-Invasive Vasospasm Diagnosis

Non-invasive coronary vasospasm diagnosis by means of echocardiography with the administration of ergonovine can be performed safely; even without prior angiography to rule out fixed lesions.

These data are encouraging and move patients with vessel spasm but without significant lesions away from multiple angiographies and from the uncertainty of a diagnosis “by exclusion.”

This work recently published in JACC Cardiovasc Imaging sought large-scale evidence to support the clinical utility of ergonovine echocardiography for the diagnosis of coronary spasms.

The test was performed in 14,012 patients (mean age 52 years; 44.3% were women) after ruling out significant coronary arterial stenosis by functional (stress electrocardiography or single photon emission computed tomography [SPECT], n = 9,824) or anatomic testing (tomography or conventional angiography, n = 4,188).

Only 0.4% of patients had to stop the study early, and a positive result was obtained in 2144 patients (15.3%). Said positive result had variable frequencies according to the presumptive diagnosis for each patient at baseline (acute coronary syndrome [38.2%], variant angina [31.8%], effort angina [14.9%], aborted sudden cardiac death [17.6%], and syncope [9.9%]).


Read also: Diabetes Could Decide between Ticagrelor and Prasugrel.


There were no mortality or infarction events during the study with ergonovine.

During a median follow-up of 11.4 years (range: 7.2 to 15.8), all-cause death and cardiovascular death occurred in 494 and 143 patients, respectively.

Compared with patients with positive ergonovine test results, the functional test group and the anatomic test group did not show a significant difference in events.


Read also: How To De-Escalate Prasugrel After Acute Coronary Syndrome?


After multiple adjustments, having a positive ergonovine echocardiogram was an independent factor linked to all-cause mortality (hazard ratio [HR]: 1.879, p < 0.001) and cardiovascular death (HR: 2.903, p < 0.001).

Conclusion

Ergonovine echocardiography may be a safe diagnostic tool for coronary vasospasm, even without anatomic documentation. These results have major long-term prognosis implications, and might even replace invasive provocation testing.

Original Title: Diagnostic and Prognostic Value of Ergonovine Echocardiography for Noninvasive Diagnosis of Coronary Vasospasm.

Reference: Sang Yong Om et al. JACC Cardiovasc Imaging. 2020 Sep;13(9):1875-1887. doi: 10.1016/j.jcmg.2020.03.008.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...